Erratum (DOI:10.1016/S1470-2045(08)70341-3);Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

The Lancet Oncology

Volumn 10, Issue 2, 2009, Pages 135-146

  Kenemans, Peter ^a   Bundred, Nigel J ^b   Foidart, Jean Michel ^c   Kubista, Ernst ^d   von Schoultz, Bo ^e   Sismondi, Piero ^f   Vassilopoulou Sellin, Rena ^g   Yip, Cheng Har ^h   Egberts, Jan ⁱ   Mol Arts, Mirjam ⁱ   Mulder, Roel ⁱ   van Os, Steve ⁱ   Beckmann, Matthias W ^j  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; GONADORELIN DERIVATIVE; PLACEBO; TAMOXIFEN; TIBOLONE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE PAIN; BREAST CANCER; BREAST DISEASE; BREAST SURGERY; BRONCHITIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTITIS; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FATIGUE; FATTY LIVER; FEMALE; FOLLOW UP; GASTRITIS; GYNECOLOGIC CANCER; HEMORRHOID; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFLUENZA; INSOMNIA; ISCHEMIC HEART DISEASE; LIMB PAIN; LUNG CANCER; LYMPH NODE METASTASIS; LYMPHADENOPATHY; LYMPHEDEMA; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SPONDYLARTHRITIS; SPOTTING; THYROID CANCER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINITIS; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VERTIGO; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WRIST FRACTURE;

EID: 58749098915     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70055-5     Document Type: Erratum

References (30)

1. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
2. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M., and Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17 (1999) 2365-2370
3. Hickey M., Saunders C.M., and Stuckey B.G. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol 6 (2005) 687-695
4. Col N.F., Hirota L.K., Orr R.K., Erban J.K., Wong J.B., and Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 19 (2001) 2357-2363
5. Modelska K., and Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87 (2002) 6-23
6. Kenemans P., and Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 51 (2005) 21-28
7. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 76 (2001) 231-238
8. De Gooyer M.E., Deckers G.H., Schoonen W.G., Verheul H.A., and Kloosterboer H.J. Receptor profiling and endocrine interactions of tibolone. Steroids 68 (2003) 21-30
9. Lundström E., Christow A., Kersemaekers W., et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 186 (2002) 717-722
10. Valdivia I., Campodónico I., Tapia A., Capetillo M., Espinoza A., and Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 81 (2004) 617-623
11. Conner P., Christow A., Kersemaekers W., et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment. Climacteric 7 (2004) 50-58
12. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
13. Opatrny L., Dell'Aniello S., Assouline S., and Suissa S. Hormone replacement therapy use and vartiations in the risk of breast cancer. Br J Obstet Gynaecol 115 (2008) 169-175
14. Cummings S.R., Ettinger B., Delmas P.D., et al. The effects of tibolone in older postmenopausal women. N Engl J Med 359 (2008) 697-708
15. Kroiss R., Fentiman I.S., Helmond F.A., et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 112 (2005) 228-233
16. Dimitrakakis C., Keramopoulos D., Vourli G., Gaki V., Bredakis N., and Keramopoulos A. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. Climacteric 8 (2005) 342-351
17. Pollow K., Schaffrath M., Kölbl H., et al. Phase II study of goserelin adjuvant therapy combined with exemestane with or without tibolone in premenopausal women with receptor positive, node negative mammary carcinoma: ADAGIO Study. Geburtsh Frauenheilk 65 (2005) 612-619
18. Kubista E., Planellas J.G., Dowset M., et al. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial. Clin Cancer Res 13 (2007) 4185-4190
19. Kenemans P., Kubista E., Foidart J.M., et al. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients-design and baseline data 'LIBERATE' trial. Breast 16 (2007) S182-S189
20. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
21. CPMP/EWP/021/97, Points to consider on hormone replacement therapy. The European Agency for the Evaluation of Medicinal Products (19 November 1997). http://www.emea.europa.eu/pdfs/human/ewp/002197en.pdf (accessed Oct 6, 2008).
22. Cline J.M., Register T.C., and Clarkson T.B. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 9 (2002) 422-429
23. Gallagher J.C., Baylink D.J., Freeman R., and McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86 (2001) 4717-4726
24. Verheul H.A., van Iersel M.L., Delbressine L.P., and Kloosterboer H.J. Selective tissue distribution of tibolone metabolites in mature ovariectomized female cynomolgus monkeys after multiple doses of tibolone. Drug Metab Dispos 35 (2007) 1105-1111
25. Suzuki T., Miki Y., Nakata T., et al. Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. J Steroid Biochem Mol Biol 86 (2003) 449-454
26. Von Schoultz E., Rutqvist L.E., and Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97 (2005) 533-535
27. Holmberg L., Anderson H., and HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 363 (2004) 453-455
28. Holmberg L., Iversen O.E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100 (2008) 475-482
29. Stefanick M.L., Anderson G.L., Margolis K.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 (2006) 1647-1657
30. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3243-3253